Posted: June 26, 2013 at 10:42 pm
Commercial challenges in the next generation market - Rahul Aras - World Stem Cells 2013
Rahul Aras, CEO at Juventas Therapeutics gives his presentation on #39;Commercial challenges in the next generation market: gene therapy activating cell therapy...
By: biopharmachannel
Original post:
Commercial challenges in the next generation market - Rahul Aras - World Stem Cells 2013 - Video
Posted: June 26, 2013 at 10:42 pm
Adipose Derived Stem Cells (ASDC) and COPD
COPD had brought Ron Delkie to the breaking point. With no other treatment options left to him, he decided to undergo an Adipose Derived Stem Cell (ADSC) tre...
By: indyregen
View original post here:
Adipose Derived Stem Cells (ASDC) and COPD - Video
Posted: June 26, 2013 at 11:20 am
“Shares of the Cambridge life
sciences company bluebird bio Inc. soared almost 60 percent on their
first day of trading (last) Wednesday, an impressive debut for a
business that endured years of stagnation and another encouraging
sign for the biotechnology industry.
“The local gene therapy company
raised $101 million in an initial public offering priced at $17 per
share, higher than the $14 to $16 estimated by investment bankers.
Bluebird shares closed at $26.91 per share on Wednesday.”
“Bluebird Bio, one of the oldest
companies in the struggling gene therapy field, is having an
outstanding first day in the stock market today, and largely by
marrying its gene therapy technology with stem cell science. The
company’s financial milestone brings hope and excitement to both
fields.”
“One of the main goals of
California’s $3 billion stem cell research agency is to draw
companies into the state so they can vie for a share of the funding.
"With a recently funded $32 million
initiative, the California
Institute for Regenerative Medicine(CIRM) has attracted two of
the biggest US players in stem cell banking to Novato, CA, to form
one of the largest biobanks of induced pluripotent stem cells (iPS
cells) in the world.”
Posted: June 25, 2013 at 1:52 pm
June 24, 2013 A promising new treatment for breast cancer being developed at Virginia Commonwealth University Massey Cancer Center and the VCU Institute of Molecular Medicine (VIMM) has been shown in cell culture and in animal models to selectively kill cancer stem cells at the original tumor site and in distant metastases with no toxic effects on healthy cells, including normal stem cells. Cancer stem cells are critical to a cancer's ability to recur following conventional chemotherapies and radiation therapy because they can quickly multiply and establish new tumors that are often therapy resistant.
The study, published in the International Journal of Cancer, focuses on a gene originally cloned in the laboratory of primary investigator Paul B. Fisher, M.Ph., Ph.D. The gene, melanoma differentiation associated gene-7 (mda-7), also known as interleukin (IL)-24, has been shown to directly impact two forms of cell suicide known as apoptosis and toxic autophagy, regulate the development of new blood vessels and also play a role in promoting cancer cell destruction by the immune system. In the present study, the researchers used a recombinant adenovirus vector, an engineered virus with modified genetic material, known as Ad.mda-7 to deliver the mda-7/IL-24 gene with its encoded protein directly to the tumor.
"Therapy with the mda-7/IL-24 gene has been shown to be safe in a phase I clinical trial involving patients with advanced cancers, and prior studies in my laboratory and with collaborators have shown that the gene could also be effective against breast, prostate, lung, colorectal, ovarian, pancreatic and brain cancers," says Fisher, Thelma Newmeyer Corman Endowed Chair in Cancer Research and co-leader of the Cancer Molecular Genetics program at VCU Massey, chairman of VCU School of Medicine's Department of Human and Molecular Genetics and director of the VCU Institute of Molecular Medicine. "Our study demonstrates that this therapy may someday be an effective way to eradicate both early and advanced stage breast cancer, and could even be used to reduce the risk of cancer recurrence."
The researchers found that infection of human breast cancer cells with the adenovirus decreased the proliferation of breast cancer stem cells without affecting normal breast stem cells. It was also shown to induce a stress response in the cells that led to apoptosis by disrupting Wnt/B-catenin signaling, a process cells rely upon to transmit signals that initiate biological functions critical to survival. In mouse models, the therapy profoundly inhibited the growth of tumors generated from breast cancer stem cells and also killed cancer cells in distant, uninjected tumors.
Since discovering the mda-7/IL-24 gene, Fisher and his team have worked to develop better ways to deliver it to cancer cells, including two cancer "terminator" viruses known as Ad.5-CTV and Ad.5/3-CTV. Cancer terminator viruses are unique because they are designed to replicate only within cancer cells while delivering immune-modulating and toxic genes such as MDA-7/IL-24. Coupled with a novel stealth delivery technique known as ultrasound-targeted microbubble destruction (UTMD), researchers can now systemically deliver viruses and therapeutic genes and proteins directly to tumors and their surrounding tissue (microenvironment) at both primary and metastatic tumor sites. UTMD uses microscopic, gas-filled bubbles that can be paired with viral therapies, therapeutic genes and proteins, and imaging agents and can then be released in a site and target-specific manner via ultrasound. Fisher and his colleagues are pioneering this approach and have already reported success in experiments utilizing UTMD technology and mda-7/IL-24 gene therapy in prostate and colorectal cancer models.
"We are hopeful that this targeted gene therapy could be safely combined with conventional chemotherapies to significantly improve outcomes for patients with breast cancer and potentially a variety of other cancers," says Fisher. "When paired with promising new delivery techniques such as UTMD, physicians may one day be able to better target site-specific cancers and also monitor the effectiveness of these types of therapies in real time."
Continued here:
Targeted viral therapy destroys breast cancer stem cells in preclinical experiments
Posted: June 25, 2013 at 1:52 pm
ALBANY, New York, June 25, 2013 /PRNewswire/ --
According to a new market report published by Transparency Market Research (http://www.transparencymarketresearch.com) "Stem Cells Market (Adult, Human Embryonic , Induced Pluripotent, Rat-Neural, Umbilical Cord, Cell Production, Cell Acquisition, Expansion, Sub-Culture)-Global Industry Analysis, Size, Share, Growth, Trends and Forecast,2012-2018," the market for stem cells was valued at USD 26.23 billion in 2011 and is expected to reach an estimated value of USD 119.51 billion in 2018, growing at a CAGR of 24.2% from 2012 to 2018.
Browse the full report athttp://www.transparencymarketresearch.com/stem-cells-market.html
The market growth is majorly attributed to therapeutic research activities led by government support worldwide owing to the growing number of patients with chronic diseases across the globe. In addition, rising awareness of regenerative treatment options and growing importance of stem cell banking services are also fostering the growth of the market. Apart from these, development of medical tourism hubs in developing nations such as India and China and in turn migration of patients from developed nations such as the U.S., and Europe for quality treatment at significantly lower prices will also serve the market as a driver especially for the Asian stem cells market.
Stem cells market will be driven by rising proportion of patients with neurological and other chronic conditions and rising disposable incomes of patients induced by economic growth of Asian regions in the next five years In addition, increasing dependence on stem cells for drug discovery and screening will boost the growth of the market in future. Increased outsourcing of contract research and clinical trials to developing Asian regions will further encourage growth of the stem cells market.
Adult stem cells held majority share of the overall stem cells market in 2011 at over 80%. This is due to less laborious procedure of harvesting, and less probability of contamination during expansion and sub-culture of adult stem cells. However, fewer post-transplant complications and lesser risk of graft vs. host reaction from the recently introduced induced pluripotent stem cells will lead to its rapid inclusion in research activities and help the global induced pluripotent stem cells market to grow at a relatively faster CAGR during the forecast period.
Related & Recently Published Reports by Transparency Market Research
http://www.transparencymarketresearch.com/coronary-stents-market.html
http://www.transparencymarketresearch.com/weight-management-market.html
http://www.transparencymarketresearch.com/magnetic-resonance-imaging-market.html
Posted: June 25, 2013 at 1:52 pm
Keynote address - Lord John Krebs - World Stem Cells Regenerative Medicine Congress
Lord John Krebs, chairman of the House of Lords Science and Technology Committee gives his presentation on #39;Mapping a route for the commercialisation of cell...
By: biopharmachannel
Continue reading here:
Keynote address - Lord John Krebs - World Stem Cells Regenerative Medicine Congress - Video
Posted: June 25, 2013 at 1:52 pm
ILOILO CITY, Iloilo (PIA) - Stem cell therapy is now available in Iloilo, specifically at St. Paul's Hospital (SPHI), a premier health care provider here.
The first hospital-based stem cell and regenerative medicine facility in this city was recently launched, with a signing of a memorandum of agreement (MOA) by SPHI, the MedicalConglomerate of Asia, Africa and Oceania, Inc. (MCAAO), and the Iloilo City government.
SPHI Kidney Center Head and Stem Cell medicine coordinator Dr. Helen Caro-Pastolero said the partnership venture identifies SPHI as the medical hub and the MCAAO as technology service provider, with the city government providing support for the medical tourism-categorized project.
St. Paul's hospital administrator, Sister Rosamond Marie Abadesco said ''After months of preparation and planning we are now almost ready to open this innovative program for the people of Iloilo.''
Stem cell medicine is an innovative program involving the engineering of living cells and tissue which are preserved to enhance organ functions. The therapy offers treatment for diabetes, arthritis, Parkinson's Diseases, Alzheimer's disease, among other disorders.
Mayor Jed Patrick Mabilog said the launching of SPHI's stem cell medical service ''definitely puts the city in the medical tourism industry map and gives an additional boost to Iloilo City as it gears for premier city status.
''We are fast becoming an emerging haven for businesses and investors as well as medical tourists who are keen about our services in terms of health and wellness,'' said Mabilog who also disclosed that aside from the city's positioning itself as a potential Asian Pacific Economic Cooperation (APEC) Summit host in 2015 and the Association of Southeast Asian Nations (ASEAN) Summit in 2017, he has also received communication from the United Nations (UN) ''asking if Iloilo City could host the UN Urban Environmental Accords world conference in 2016.''
Meanwhile, MCAAO Inc. president Dr. Leo Olarte said he is happy that stem cell treatment has been accepted in this part of the country because ''it is for the best interest of patients needing stem cell medical therapy.''
''We hope that our joint venture with SPHI in stem cell therapy will highlight Iloilo's potentials as an ideal medical tourism destination in this part of the country,'' said Olarte.
He informed that the SPHI stem cell facility will utilize the Autologous stem cell transplantation therapy in which stem cells (cells from which other cells of the same type develop) are removed, stored, and later given back to the same person from whom such cells were harvested.
Read the original:
Regenerative medicine now in Iloilo
Posted: June 25, 2013 at 1:52 pm
DUBLIN--(BUSINESS WIRE)--
Research and Markets (http://www.researchandmarkets.com/research/23dgtg/regenerative) has announced the addition of the "Regenerative Medicine Markets" report to their offering.
Regenerative medicine is a way of treating injured and diseased human tissue by using laboratory-grown or therapeutically-induced human tissue as a replacement.
This TriMark Publications report discusses the current state of regenerative medicine. The study provides a thorough overview of regenerative medicine sector together with analyses of the funding trends, intellectual property, market opportunities, therapeutic pipeline, research collaborations, partnership activities, and guidelines for establishing new ventures.
The report enables the reader gain in-depth knowledge about ongoing tissue engineering and stem cell therapy research programs carried out in universities and other research centers. Moreover, this analysis profiles the leading companies developing regenerative medicine solutions.
Key Topics Covered
1. Overview
2. Regenerative Medicines: An Overview of Segments
3. Regenerative Medicine: The Next Evolution of Medical Treatment
4. Recent Advances in Regenerative Medicine and Stem Cell Research
See the original post here:
Research and Markets: Regenerative Medicine Markets - 2013 Report
Posted: June 25, 2013 at 1:50 pm
MANILA - House Speaker Sonny Belmonte said 2 congressmen died after having stem cell therapy overseas.
These are congressmen Erico Aumentado and Pedro Romualdo.
Belmonte, however, clarified that it has not been established whether stem cell therapy was the cause of death.
Belmonte said that after having stem cell therapy, the 2 felt rejuvenated and may have exerted themselves during the last election campaign.
Belmonte said Aumentado even started walking around without a cane.
Aumentado' son Aristotle, a first-term congressman, was introduced by Belmonte to media during the sidelines of the executive course the lower House sponsored for neophytes.
Aristotle said his father died of pneumonia. He added there is also no proof that stem cell caused the death.
In fact, he said they were scheduled for another treatment after the elections had his father not died.
Aristotle said the Philippine Medical Association (PMA) has not approached them for the PMA's investigation into the deaths of 3 politicians who died after receiving stem cell therapy abroad.
Aristotle explained that his father had leg thrombosis for which he had to undergo bifemoral bypass and stem cell therapy .
See the original post here:
2 congressmen who died after stem cell therapy named
Posted: June 25, 2013 at 1:50 pm
Manila, Philippines --- Several congressmen have indeed undergone stem cell therapy in Germany and two of them died while serving the 15th Congress.
This was gathered from several sources as one outgoing congressman disclosed that a group of Mindanao mayors are set to depart for Europe to visit stem cell clinics in Germany.
''But virility and aesthetic enhancements are the reasons for the trip,'' said outgoing Agham Party-list Rep. Angelo Palmones in an interview yesterday.
Palmones admitted that one of the veteran solons who died during the 15th Congress was a stem cell therapy patient but whether or not the procedure contributed to his death remains unknown.
''He died of heart attack but the purpose of his stem cell treatment was to improve virility,'' said Palmones, outgoing vice chairman of the House Committee on Science and Technology.
Two others reportedly flew to Europe to seek treatment for cancer but both died.
A former broadcaster, Palmones authored House Resolution No. 1075 calling for a congressional investigation in aid of legislation on the operation of stem cell therapy clinics in malls in a bid to ensure the ''safety and security of patients.''
In a press statement the other day, the Philippine Medical Association (PMA) aired suspicions that ''three politicians'' from Mindanao may have died due to stem cell treatments from unauthorized practitioners.
Read this article:
Was Stem Cell therapy behind death of 3 Solons?
Source: